Alnylam Pharmaceuticals' RNA interference drug zilebesiran for hypertension did not meet the primary blood pressure-lowering endpoint in a late-stage Phase 2 trial. Despite the setback, Roche, which co-develops the drug, considers the data encouraging enough to advance into a Phase 3 cardiovascular outcomes trial, KARDIA-3, aiming to assess longer-term effects. The trial showed modest blood pressure reductions but lacked statistical significance. The results were revealed at the 2025 European Society of Cardiology meeting.